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Abstracts 
Background: Serine proteases have important roles in skin barrier function and 
desquamation, and the aberrant expression or the dysfunction of serine proteases is 
associated with the pathogenesis of skin diseases. Serine protease activities are tightly 
regulated by serine proteases such as kallikrein-related peptidases (KLKs) and serine 
protease inhibitors such as lympho-epithelial Kazal-type related inhibitor (LEKTI). For 
a better understating of diseases' pathogenesis, the regulation mechanism of serine 
proteases and the inhibitors' expression in epidermal keratinocytes must be clarified. 
Objectives: To investigate the effects of the cytokines on the expression of LEKTI in 
epidermal keratinocytes.  
Methods: Normal human epidermal keratinocytes (NHEKs) were stimulated with 
panels of inflammatory cytokines. The expression of serine protease inhibitors was 
analyzed using quantitative real-time PCR and ELISA. LEKTI expression in normal 
human skin and lesions from psoriasis or atopic dermatitis (AD) were analyzed by 
immunohistochemically and tape-stripping. Trypsin- and chymotrypsin-like serine 
protease activities in culture supernatants were measured by using specific substrates.  
Results: TNF-α and IL-17A significantly induced the expression of LEKTI in NHEKs. 
The immunohistochemical and tape-stripping analysis revealed that psoriatic skin 
lesions had higher LEKTI expression compared to normal skin and AD lesions. Trypsin- 
and chymotrypsin-like protease activities in the culture media were upregulated 3-5 
days later but attenuated 6-7 days later period by these cytokines.  
Conclusions: In epidermal keratinocytes, the Th1&Th17 cytokines TNF-α and IL-17A 
induce the expression of serine protease inhibitor LEKTI, and it might occur to suppress 
 3 / 21 
 
the increase in the serine protease activities under inflammation. 
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1. Introduction 
Serine proteases have important roles in the skin barrier function and desquamation. 
Kallikrein-related peptidases (KLKs) are 15 trypsin- or chymotrypsin-like serine 
proteases, and in the skin, KLK5 and KLK7 in particular have a prominent role in 
desquamation. [1] These two KLKs are produced mainly by keratinocytes of the stratum 
granulosum, and they degrade the corneodesmosome proteins such as desmoglein 1, 
desmocollin 1, and corneodesmosin. [2] The aberrant expression or the dysfunction of 
serine proteases is associated with the pathogenesis of skin diseases such as atopic 
dermatitis (AD), psoriasis, Netherton syndrome, and rosacea. [1, 3-8] Hasson et al. 
reported that transgenic mice overexpressing human KLK7 developed chronic itchy 
dermatitis. [9] Furio et al. also showed that transgenic mice that express human KLK5 
display severe skin inflammation and allergy with pruritus. [10]  
The serine protease activities are tightly regulated by serine proteases such as KLKs 
and serine protease inhibitors including lympho-epithelial Kazal-type related inhibitor 
(LEKTI) encoded by SPINK5, secretory leukocyte peptidase inhibitor (SLPI), and elafin 
encoded by PI3. [1, 2] LEKTI is a major serine protease inhibitor in the skin; it is 
expressed in the differentiated epidermal layer. [1, 11] LEKTI has 15 Kazal-type 
domains (D1 to D15), and each of them functions as the protease inhibitor. [3, 12] 
Furthermore, the fragments of LEKTI processing, including D6D9, D7D9, D8D9, 
D10D15, and D10D13, are also bioactive. [3] The nonsense mutations of SPINK5 lead 
to Netherton syndrome that is characterized by ichthyosis, hair abnormalities (‘bamboo 
hair’), and atopic manifestations. [3, 6] Spink5-deficient mice replicate Netherton 
syndrome and demonstrate LEKTI as a key regulator of epidermal protease activity. [7] 
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In addition, a single nucleotide polymorphism (SNP) pK420E has been reported to 
change the serine protease inhibitor activity and to be associated with AD. [13]  
For a better understanding of the skin diseases' pathogenesis, the regulation 
mechanism of LEKTI expression in epidermal keratinocytes must be clarified. 
Previously our group reported that calcium but not 1,25-dihydroxyvitamin D3 or 
retinoic acid induces the expression of LEKTI in the cell, and that Toll-like receptor 
signaling induces the expression. [14, 15] However, the effect of inflammatory 
cytokines expressed in skin diseases’ lesions on LEKTI expression has not been 
evaluated. Here we report that the Th1 cytokine TNF-α and the Th17 cytokine IL-17A 
induce the expression of LEKTI in epidermal keratinocytes. 
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2. Materials and methods 
 
2.1. Human samples  
This study was approved by the Ethics Committee of Okayama University (No. 1611-
002). Skin samples were collected with written informed consent from patients with 
atopic dermatitis (AD) or psoriasis and from normal healthy volunteers at Okayama 
University Hospital. After the injection of local anesthesia, 3-mm punch biopsies were 
collected from the untreated lesional skin of the individuals with AD or psoriasis and from 
normal healthy volunteers. Formalin-fixed, paraffin-embedded skin samples were cut into 
4-µm sections, and the specimens were used for immunohistochemical studies. The scale 
samples were obtained from the forearm of normal healthy volunteers and acute skin 
lesions of trunk, limbs or neck of AD or psoriasis. We collect the scale samples using 
Nichiban tape (LP-24, Nichiban, Tokyo, Japan).  
  
  
2.2. Tape-stripping protein extraction 
The scale samples on the tapes were immediately stored at -20℃. The tapes were 
dipped into 10mL of toluene and shook strongly. After the insoluble tapes were 
removed, the samples were centrifuged at 1,700g for 15 min, 20℃. We aspirated the 
toluene leaving scale pellets and washed them with 5mL of toluene five times in order 
to remove any residual adhesive. After the last wash, the pellets were suspended in 1mL 
toluene and centrifuged at 1,700g for 15 min, 20℃. After decanting the toluene, and the 
pellets were dried up and then dissolved in RIPA buffer (Thermo scientific, Rockford, 
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IL, USA) with Protease Inhibitor Cocktail Tablets (Roche Diagnostics, Indianapolis, IN, 
USA). The pellets were treated with Ultrasonic Homogenizer VP-050(TAITEC, 
Saitama, Japan) 20% power for 20 sec, 4℃. The samples were centrifuged at 1,700g for 
15min at 4℃. Total protein concentration of the samples was measured with Bio-Rad 
DC Protein Assay (Bio-Rad, Hercules, CA, USA) and standardized by density. [16] 
 
2.3. Cell culture and stimuli  
Normal human epidermal keratinocytes (NHEKs) were obtained from Cascade 
Biologics/Invitrogen (Portland, OR, U.S.A.) and grown in serum-free EpiLife cell 
culture media (Cascade Biologics/Invitrogen) containing 0.06 mM Ca2+ and 1× EpiLife 
Defined Growth Supplement (EDGS, Cascade Biologics/Invitrogen) at 37 °C under 
standard tissue culture conditions. Cultures were maintained for up to seven passages in 
this media with the addition of 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 
µg/ml amphotericin B. NHEKs were grown in 24-well flat bottom plates (Corning 
Incorporated, Corning, NY, U.S.A). Upon reaching 30-80% confluence, NHEKs were 
stimulated for up to 168h. Cells were stimulated with IL-4 (50 ng/ml; R&D Systems, 
Minneapolis, MN, U.S.A.), IL-13 (50 ng/ml; R&D systems), IL-17A (10-100 ng/ml; R 
& D systems), IL-22 (50 ng/ml; R&D Systems), IL-33 (50 ng/ml; R&D Systems), TNF-
α (10-100 ng/ml; eBioscience, San Diego, CA, U.S.A.), IFN-γ (50 ng/ml, Sigma-
Aldrich, St Louis, MO, U.S.A.), and phosphate-buffered saline (PBS) as vehicle in 24-
well flat-bottom plates (Corning, Lowell, MA, U.S.A.) for up to 168 hr. After cell 
stimulation, the total cell media were stored at −20 °C until analysis. RNA was 
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, U.S.A.) after supernatant 
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collection. The RNA was stored at −80 °C until use.  
  
2.4. Quantitative real-time PCR  
Complementary DNA (cDNA) was synthesized from RNA using the iScript cDNA 
Synthesis Kit (BioRad, Hercules, CA, U.S.A.) as described by the manufacturer. 
TaqMan gene Expression Assays (Applied Biosystems ABI, Foster City, CA, U.S.A.) 
were used to analyze the expression of human SPINK5 (assay ID: Hs00199260_m1), 
SLPI (assay ID: Hs00268204_m1), PI3 (assay ID: Hs00160066_m1), KLK5 (assay ID: 
Hs00202752_m1), KLK6 (assay ID: Hs00160519_m1), KLK7 (assay ID: 
Hs00192503_m1), KLK8 (assay ID: Hs01012737_m1), KLK10 (assay ID: 
Hs00173611_m1), KLK11 (assay ID: Hs01100849_m1), KLK13 (assay ID: 
Hs01087307_m1), and KLK14 (assay ID: Hs00222788_m1) as described by the 
manufacturer (User Bulletin #2, Applied Biosystems). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as an internal control to validate the RNA for each 
cultured keratinocyte sample. GAPDH mRNA was detected using the VIC-
CATCCATGACAACTTTGGTA-MGB probe with the primers 5'-
CTTAGCACCCCTGGCCAAG-3' and 5'-TGGTCATGAGTCCTTCCACG-3'. Each 
mRNA expression was calculated as the expression relative to GAPDH mRNA, and all 
data are presented as the fold-change in comparison with each control (the mean value 
of the non-stimulated cells).  
  
2.5. ELISA  
  The LEKTI protein levels in the culture supernatants and tape-stripping standardized 
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samples were measured with a commercial sandwich ELISA, according to the 
manufacturer's protocol (Cloud-Clone, Houston, TX, U.S.A.) Absorbance at 450 nm 
was determined using a microplate reader (SH-1000Lab, Corona Electric, Hitachinaka, 
Japan).  
  
2.6. Protease assay  
  Protease activity in cultured media was measured by protease assay with the 4-
Methylcoumaryl-7-amide (MCA) as fluorescent substrates. When specific enzymes 
cleave the bond between the peptide moiety and MCA, fluorescent 7-amino-4-
methylcoumarin (AMC) is released. We selected the specific substrates, Boc-Phe-Ser-
Arg-MCA for trypsin-like protease, or Phe-MCA for chymotrypsin-like protease (3148-
v or 3107-v, respectively, Peptide Institute, Osaka, Japan). One hundred µl of the 
cultured media was mixed with 100 µl of each substrate in 10 mM Tris-HCl buffer, pH 
7.8, into a 96-well black plate (Corning) and incubated at 37 °C for 24 hr. Protease 
activity was monitored as increased fluorescence (excitation/emission = 380/460nm) 
with a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, 
CA, U.S.A.) at the Central Research Laboratory, Okayama University Medical School.  
 
2.7. Immunohistochemistry  
Formalin-fixed, paraffin-embedded skin samples were cut into 4-µm sections and 
mounted on glass slides. The slides were deparaffinized and incubated with hydrogen 
peroxide for 5 min and blocked with 10% goat-serum in PBS for 10 min at room 
temperature. The sections were then incubated with the rabbit polyclonal anti-human 
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SPINK5 antibody (NBP1-90509, Novus Bio-Techne, Littleton, CO, U.S.A.) at 4 °C 
overnight. The slides were incubated with biotinylated anti-rabbit IgG polyclonal 
antibody and then streptavidin-HRP (K0675, Dako, Tokyo). Histochemical visualization 
was carried out with 3-Amino-9-ethylcarbazole (AEC) (Dako).  
 
2.8. Statistical analysis  
Results are expressed as the mean±standard error of the mean (SEM). Student's t-test 
was used to determine the significance of differences between the two groups. A one-
way analysis of variance (ANOVA) with Tukey's test was used to determine the 
significance of differences among more than two groups. The analyses were performed 
using GraphPad Prism 4 (GraphPad Software, La Jolla, CA, U.S.A.). A p-value <0.05 
was considered significant.  
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3. Results 
Here we analyzed the effect of inflammatory cytokines on LEKTI expression in 
normal human epidermal keratinocytes (NHEKs). We performed an ELISA, which 
revealed that the Th1 cytokine TNF-α and the Th17 cytokine IL-17A significantly 
increased LEKTI protein in culture media of NHEKs (Fig. 1A). A real-time quantitative 
PCR analysis showed that the expression of the transcript, SPINK5, was also 
upregulated in parallel to protein in NHEKs (Fig. 1B). In addition, the induction of 
LEKTI by TNF-α and IL-17A was dose- and time-dependent (Fig. 1C-F). The mRNA 
expressions of other serine protease inhibitors, SLPI and PI3, were also significantly 
increased by TNF-α and IL-17A (Fig. 1G and H). On the other hand, the Th2 cytokines 
IL-4 and IL-13 significantly suppressed the expression of SLPI and PI3 in NHEKs (Fig. 
1G and H). 
To investigate the clinical relevance of these in vitro findings, we analyzed the 
LEKTI expression in normal human skin and lesions from psoriasis or AD. We 
evaluated immunostaining results by scoring the degrees of stain color and pattern. 
Since the granular layer is always strongly positive for LEKTI staining, we scored the 
epidermis excluding this layer. The immunohistochemical analysis and LEKTI ELISA 
using the scale samples revealed that keratinocytes from psoriasis skin lesions had 
significantly higher LEKTI expression compared to normal skin and AD lesions (Fig. 
2A and B). There was no significant difference in LEKTI expression between the 
normal skin and AD lesions. 
Furthermore, we examined the functional relevance of our results, i.e., the trypsin- 
and chymotrypsin-like serine protease activities, in NHEKs stimulated with TNF-α and 
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IL-17A. Both the trypsin- and chymotrypsin-like serine protease activities in the cells 
were increased at 72, 96, and 120 hr after the TNF-α and IL-17A stimulation (Fig. 3). 
However, the increases were attenuated at 144 and 168 hr after the stimulation. Since 
the serine protease activities were upregulated by TNF-α and IL-17A, we also examined 
the expressions of KLK5, 6, 7, 8, 10, 11, 13, and 14 in NHEKs. [16] TNF-α and IL-17A 
significantly increased the expression of KLK6, 10, 11, and 13 in NHEKs (Fig. 4). 
KLK14 expression was not consistently detectable in our keratinocyte culture system, 
as previously reported. [17] 
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4. Discussion 
KLK5 and KLK7 are known as the major serine proteases in the skin. Previously we 
reported that Th2 but not Th1 or Th17 cytokines induce the expression of KLK7 in 
epidermal keratinocytes. [17, 18] Here we demonstrated that the Th1 cytokine TNF-α and 
the Th17 cytokine IL-17A induce the expression of LEKTI, the major inhibitor of KLK5 
and KLK7, in epidermal keratinocytes. SPINK5 mRNA expression was only induced 1.25 
or 1.5-fold by these cytokines. TNF-α and IL-17A might increase mainly LEKTI release 
dependent on calcium flux rather than the transcription. [19] 
The Th1 cytokine IFN-γ and the Th17 cytokine IL-22 did not induce LEKTI (SPINK5), 
SLPI, and elafin (PI3) expression (Fig. 1A, B, G and H). Both TNF-α and IL-17A 
signaling leads to NF-κB and AP-1 activation but IFN-γ and IL-22 do not. We 
hypothesized that the induction of LEKTI is dependent on these transcription factors, and 
performed siRNA experiments by using NF-κBp65 siRNA and c-Jun siRNA. The 
knockdown of NF-κBp65 or c-Jun did not significantly suppress the induction of LEKTI, 
SLPI, or elafin by TNF-α and IL-17A in NHEKs (data not shown). These results suggest 
that some NF-κB/AP-1-independent mechanisms are involved in the induction of the 
serine protease inhibitors by TNF-α and IL-17A in epidermal keratinocytes. This is the 
future direction to be investigated. 
Th1 and Th17 cytokines are thought to play critical roles in the pathogenesis of 
psoriasis, whereas AD is a Th2 disease characterized by the predominance of the Th2 
cytokines IL-4 and IL-13. [11, 20] In previous studies, LEKTI expression was reported 
to be increased in upper epidermis of psoriatic lesions. [21, 22] The expression in AD 
lesions were controversial. [21-24] In addition, we recently reported that the expression 
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of LEKTI was up-regulated in lesions of varicella, pyoderma, and rosacea. [14] Our 
present analyses showed that keratinocytes from psoriasis but not AD skin lesions had 
significantly higher LEKTI expression compared to normal skin. Granular layers always 
highly express LEKTI. However, psoriatic lesions do not have granular layers, but the 
psoriatic basal and spinous layers visibly express LEKTI in the lesions but not in normal 
skins. We needed to evaluate the increase in LEKTI expression in skin diseases fairly. 
Therefore, we excluded granular layers in order to correctly evaluate spinous and basal 
layers in this study. Our in vitro results might explain why LEKTI expression in AD 
patients is not increased like that in psoriasis patients. 
On the other hand, TNF-α and IL-17A significantly enhanced trypsin- and 
chymotrypsin-like protease activities in the culture supernatants of epidermal 
keratinocytes 72–120 hr post-stimulation, but the enhancement gradually disappeared 
by 144–168 hr. Serine protease activities are controlled by the balance between serine 
proteases and the inhibitors. These cytokines induced the expression of KLK6, KLK10, 
KLK11, and KLK13 as well as the inhibitors in NHEKs. The expression of KLK5, 
KLK7, and KLK8 were not changed by the stimulation in the cells (data not shown). 
The increases in trypsin-like serine protease activity after the stimulation might be due 
to the enhancement of transcription of KLKs. On the other hand, TNF-α and IL-17A 
also might activate some chymotrypsin-like serine proteases rather than KLK7 in 
NHEKs. The reduction at 144 and 168 hr after the stimulation might be due to the 
induction of LEKTI, SLPI, and elafin expression. 
The lesional skin of AD and psoriasis has various degrees of scales. The epidermis 
might upregulate the serine protease activities under inflammation based on the 
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necessity of removing scales including pathogens and allergens, and it might also stop 
the activities through the increase of serine protease inhibitors after inflammation. Also, 
biologics including anti-TNF-α and anti-IL-17 antibodies improves psoriasis lesions 
quite effectively by suppressing inflammation that is induced by those cytokines. These 
agents might improve the dyskeratosis by inhibiting the LEKTI secretion. Further 
investigations are required to clarify which KLKs are responsible for the increase in the 
activities of the cells, and how the inhibitors induced by TNF-α and IL-17A are 




This work was supported by a Grant-in-Aid for Scientific Research(C)(no.26461658) 
and a grant from the Japanese Dermatological Association (Shiseido Award). 




[1] A.V. Rawlings, R. Voegeli, Stratum corneum proteases and dry skin conditions, Cell and tissue 
research 351(2) (2013) 217-35. 
[2] C. Caubet, N. Jonca, M. Brattsand, M. Guerrin, D. Bernard, R. Schmidt, T. Egelrud, M. Simon, G. 
Serre, Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, 
SCTE/KLK5/hK5 and SCCE/KLK7/hK7, The Journal of investigative dermatology 122(5) (2004) 1235-
44. 
[3] A. Hovnanian, Netherton syndrome: skin inflammation and allergy by loss of protease inhibition, Cell 
and tissue research 351(2) (2013) 289-300. 
[4] U. Meyer-Hoffert, Reddish, scaly, and itchy: how proteases and their inhibitors contribute to 
inflammatory skin diseases, Archivum immunologiae et therapiae experimentalis 57(5) (2009) 345-54. 
[5] K. Yamasaki, A. Di Nardo, A. Bardan, M. Murakami, T. Ohtake, A. Coda, R.A. Dorschner, C. 
Bonnart, P. Descargues, A. Hovnanian, V.B. Morhenn, R.L. Gallo, Increased serine protease activity and 
cathelicidin promotes skin inflammation in rosacea, Nat Med 13(8) (2007) 975-80. 
[6] S. Chavanas, C. Bodemer, A. Rochat, D. Hamel-Teillac, M. Ali, A.D. Irvine, J.L. Bonafe, J. 
Wilkinson, A. Taieb, Y. Barrandon, J.I. Harper, Y. de Prost, A. Hovnanian, Mutations in SPINK5, 
encoding a serine protease inhibitor, cause Netherton syndrome, Nat Genet 25(2) (2000) 141-2. 
[7] P. Descargues, C. Deraison, C. Bonnart, M. Kreft, M. Kishibe, A. Ishida-Yamamoto, P. Elias, Y. 
Barrandon, G. Zambruno, A. Sonnenberg, A. Hovnanian, Spink5-deficient mice mimic Netherton 
syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity, Nat Genet 37(1) 
(2005) 56-65. 
[8] N. Komatsu, K. Saijoh, C. Kuk, F. Shirasaki, K. Takehara, E.P. Diamandis, Aberrant human tissue 
 17 / 21 
 
kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, 
severity and therapy, Br J Dermatol 156(5) (2007) 875-83. 
[9] L. Hansson, A. Backman, A. Ny, M. Edlund, E. Ekholm, B. Ekstrand Hammarstrom, J. Tornell, P. 
Wallbrandt, H. Wennbo, T. Egelrud, Epidermal overexpression of stratum corneum chymotryptic enzyme 
in mice: a model for chronic itchy dermatitis, The Journal of investigative dermatology 118(3) (2002) 
444-9. 
[10] L. Furio, S. de Veer, M. Jaillet, A. Briot, A. Robin, C. Deraison, A. Hovnanian, Transgenic kallikrein 
5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome, The Journal of 
experimental medicine 211(3) (2014) 499-513. 
[11] E.B. Brandt, U. Sivaprasad, Th2 Cytokines and Atopic Dermatitis, Journal of clinical & cellular 
immunology 2(3) (2011). 
[12] T. Roelandt, B. Thys, C. Heughebaert, A. De Vroede, K. De Paepe, D. Roseeuw, B. Rombaut, J.P. 
Hachem, LEKTI-1 in sickness and in health, International journal of cosmetic science 31(4) (2009) 247-
54. 
[13] P. Fortugno, L. Furio, M. Teson, M. Berretti, M. El Hachem, G. Zambruno, A. Hovnanian, M. 
D'Alessio, The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease 
deregulation: implications for atopic dermatitis, Human molecular genetics 21(19) (2012) 4187-200. 
[14] S. Sugimoto, S. Morizane, H. Nomura, M. Kobashi, S. Sugihara, K. Iwatsuki, Toll-like receptor 
signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes, J 
Dermatol Sci 92(2) (2018) 181-187. 
[15] M. Kobashi, S. Morizane, S. Sugimoto, S. Sugihara, K. Iwatsuki, Expression of serine protease 
inhibitors in epidermal keratinocytes is increased by calcium but not 1,25-dihydroxyvitamin D3 or 
retinoic acid, The British journal of dermatology 176(6) (2017) 1525-1532. 
 18 / 21 
 
[16] N. Komatsu, K. Saijoh, M. Sidiropoulos, B. Tsai, M.A. Levesque, M.B. Elliott, K. Takehara, E.P. 
Diamandis, Quantification of human tissue kallikreins in the stratum corneum: dependence on age and 
gender, J Invest Dermatol 125(6) (2005) 1182-9. 
[17] S. Morizane, K. Yamasaki, A. Kajita, K. Ikeda, M. Zhan, Y. Aoyama, R.L. Gallo, K. Iwatsuki, TH2 
cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis, J Allergy Clin 
Immunol 130(1) (2012) 259-61 e1. 
[18] S. Morizane, K. Yamasaki, F.D. Kabigting, R.L. Gallo, Kallikrein expression and cathelicidin 
processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid, J 
Invest Dermatol 130(5) (2010) 1297-306. 
[19] K. Yamasaki, K. Kanada, D.T. Macleod, A.W. Borkowski, S. Morizane, T. Nakatsuji, A.L. Cogen, 
R.L. Gallo, TLR2 expression is increased in rosacea and stimulates enhanced serine protease production 
by keratinocytes, The Journal of investigative dermatology 131(3) (2011) 688-97. 
[20] F.O. Nestle, D.H. Kaplan, J. Barker, Psoriasis, The New England journal of medicine 361(5) (2009) 
496-509. 
[21] E. Bitoun, A. Micheloni, L. Lamant, C. Bonnart, A. Tartaglia-Polcini, C. Cobbold, T. Al Saati, F. 
Mariotti, J. Mazereeuw-Hautier, F. Boralevi, D. Hohl, J. Harper, C. Bodemer, M. D'Alessio, A. 
Hovnanian, LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and 
defective expression in Netherton syndrome, Human molecular genetics 12(19) (2003) 2417-30. 
[22] C. Ong, E.A. O'Toole, L. Ghali, M. Malone, V.V. Smith, R. Callard, J.I. Harper, LEKTI demonstrable 
by immunohistochemistry of the skin: a potential diagnostic skin test for Netherton syndrome, Br J 
Dermatol 151(6) (2004) 1253-7. 
[23] D. Roedl, C. Traidl-Hoffmann, J. Ring, H. Behrendt, M. Braun-Falco, Serine protease inhibitor 
lymphoepithelial Kazal type-related inhibitor tends to be decreased in atopic dermatitis, Journal of the 
 19 / 21 
 
European Academy of Dermatology and Venereology : JEADV 23(11) (2009) 1263-6. 
[24] S. Igawa, M. Kishibe, M. Minami-Hori, M. Honma, H. Tsujimura, J. Ishikawa, T. Fujimura, M. 
Murakami, A. Ishida-Yamamoto, Incomplete KLK7 Secretion and Upregulated LEKTI Expression 
Underlie Hyperkeratotic Stratum Corneum in Atopic Dermatitis, The Journal of investigative 
dermatology 137(2) (2017) 449-456. 




Fig. 1 TNF-α and IL-17A induce the expression of LEKTI in NHEKs. NHEKs were 
stimulated with TNF-α, IL-4, -13, -17A, and -22, IFN-γ, IL-33 (50 ng/ml) and non-
stimulated cells(vehicle) for 24hr (A, B, G and H). NHEKs were stimulated with TNF-
α and IL-17A as 10, 50, 100 ng/ml and non-stimulated cells(vehicle) for 24hr (C, D). 
NHEKs were stimulated with TNF-α and IL-17A (50 ng/ml) for 0-72hr (E, F).   
LEKTI protein in the cultured media were measured by using ELISA (A and C-F). The 
relative SPINK5, SLPI and PI3(elafin) mRNA abundance against GAPDH were 
analyzed by qPCR (B, G and H). *p<0.05, **p<0.01, ***p<0.001. Data are given as 
mean±SEM of triplicate samples and are representative of three independent 
experiments. 
 
Fig. 2 The expression of LEKTI in psoriatic lesions is upregulated compared to 
normal skin or AD lesions. Skin samples were stained with rabbit polyclonal 
antibodies to LEKTI. NS: normal skin (n=9) AD: atopic dermatitis (n=25) PS: Psoriasis 
(n=21) We excluded granular layers and scored as follows. 0: not stained. 1: stained 
weakly in the whole epidermis. 2: stained strongly in the upper epidermis. 3: stained 
strongly in the whole epidermis (A). Tape-striping scale samples were collected from 
normal healthy volunteers, AD and PS patients. NS: (n=5) AD: (n=5) PS: (n=5) LEKTI 
protein in the scale samples were measured by using ELISA (B). *p<0.05, **p<0.01, 
***p<0.001. Data are given as mean±SEM. 
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Fig. 3 TNF-α and IL-17A change the activities of serine protease inhibitors in 
NHEKs. NHEKs were stimulated with TNF-α (50 ng/ml) and IL-17A (50 ng/ml) for 
24–168hr (A-D). Relative trypsin- (A, B) or chymotrypsin- (C, D) like serine protease 
activity to that of non-stimulated cells (vehicle) in the culture media were analyzed. 
*p<0.05, **p<0.01, ***p<0.001. Data are given as mean±SEM of triplicate samples and 
are representative of three independent experiments. 
 
Fig. 4 TNF-α and IL-17A induce the expression of KLK6, 10, 11, and 13 in NHEKs. 
NHEKs were stimulated with TNF-α (50 ng/ml) and IL-17A (50 ng/ml) for 24hr (A-D). 
The relative KLK 6, 10, 11, and 13 mRNA abundance against GAPDH were analyzed 
by qPCR. *p<0.05, **p<0.01, ***p<0.001. Data are given as mean±SEM of triplicate 
samples and are representative of three independent experiments. 
